Clinical management of cancer after kidney transplantation
Open Access
- 25 March 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1784083
Abstract
Advances in immunosuppressive therapy have markedly improved short-term graft survival post-kidney transplantation (KT); however, these advances have also profoundly altered long-term disease patterns in transplant recipients. Cancer remains a major barrier limiting improvements in long-term survival. Kidney transplant recipients are at increased risk of malignancy owing to impaired graft function and immunosuppressive medications. To improve cancer-related outcomes, comprehensive strategies encompassing prevention, early detection through screening, and appropriate treatment are required. Primary prevention includes the appropriate selection and maintenance of immunosuppressive medications, careful consideration of KT indications for recipients and donors with previously treated cancers, and vaccination. Secondary prevention requires effective, risk-adapted cancer screening in high-risk kidney transplant recipients. Following a cancer diagnosis, management includes localized resection and systemic therapy for primary, recurrent, or refractory disease. Systemic therapy includes chemotherapy and immunotherapy, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, which may affect graft function and cause treatment-specific adverse effects. Additionally, immunosuppressive medications often require modification to minimize the risk of graft rejection while maintaining a low likelihood of recurrence. In this review, we summarize current strategies for cancer prevention, screening, and treatment following KT.Keywords
This publication has 109 references indexed in Scilit:
- Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysisHepatology International, 2024
- The impact of induction therapy on the risk of posttransplant lymphoproliferative disorder in adult kidney transplant recipients with donor-recipient serological Epstein-Barr virus mismatchAmerican Journal of Transplantation, 2024
- Immunosuppression and cancer risk in kidney transplant recipients: A retrospective cohort studyInternational Journal of Cancer, 2024
- Dialysis or kidney transplantation in older adults? A systematic review summarizing functional, psychological, and quality of life-related outcomes after start of kidney replacement therapyInternational Urology and Nephrology, 2022
- Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long‐term multicenter cohort studyCancer Medicine, 2020
- Cancer mortality in kidney transplant recipients: An Australian and New Zealand population‐based cohort study, 1980–2013International Journal of Cancer, 2019
- How safe are organs from deceased donors with neoplasia? The results of the Italian Transplantation NetworkJournal Of Nephrology, 2019
- UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer2017
- Steroid avoidance or withdrawal for kidney transplant recipientsCochrane Database of Systematic Reviews, 2016
- Cancer Incidence Before and After Kidney TransplantationJAMA, 2006